Protease inhibitors and their peptidomimetic derivatives as potential drugs

被引:89
作者
Fear, Georgie [1 ]
Komarnytsky, Slavko [1 ]
Raskin, Ilya [1 ]
机构
[1] Rutgers State Univ, Biotech Ctr, New Brunswick, NJ 08901 USA
关键词
protease; protease inhibitors; therapeutic application; clinical trials; approved drugs;
D O I
10.1016/j.pharmthera.2006.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Precise spatial and temporal regulation of proteolytic activity is essential to human physiology. Modulation of protease activity with synthetic peptidomimetic inhibitors has proven to be clinically useful for treating human immunodeficiency virus (HIV) and hypertension and shows potential for medicinal application in cancer, obesity, cardiovascular, inflammatory, neurodegenerative diseases, and various infectious and parasitic diseases. Exploration of natural inhibitors and synthesis of peptidomimetic molecules has provided many promising compounds performing successfully in animal studies. Several protease inhibitors are undergoing further evaluation in human clinical trials. New research strategies are now focusing on the need for improved comprehension of protease-regulated cascades, along with precise selection of targets and improved inhibitor specificity. It remains to be seen which second generation agents will evolve into approved drugs or complementary therapies. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:354 / 368
页数:15
相关论文
共 148 条
[1]   Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients [J].
Alexis, Nell E. ;
Muhlebach, Marianne S. ;
Peden, David B. ;
Noah, Terry L. .
JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (01) :17-25
[2]   Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain [J].
Anand, K ;
Palm, GJ ;
Mesters, JR ;
Siddell, SG ;
Ziebuhr, J ;
Hilgenfeld, R .
EMBO JOURNAL, 2002, 21 (13) :3213-3224
[3]   Trypsin activation pathway of rotavirus infectivity [J].
Arias, CF ;
Romero, P ;
Alvarez, V ;
Lopez, S .
JOURNAL OF VIROLOGY, 1996, 70 (09) :5832-5839
[4]  
Armstrong WB, 2000, CLIN CANCER RES, V6, P4684
[5]   Lopinavir/ritonavir as single-drug therapy for maintenance of HlV-1 viral suppression -: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study) [J].
Arribas, JR ;
Pulido, F ;
Delgado, R ;
Lorenzo, A ;
Miralles, P ;
Arranz, A ;
González-García, JJ ;
Cepeda, C ;
Hervás, R ;
Paño, JR ;
Gaya, F ;
Carcas, A ;
Montes, ML ;
Costa, JR ;
Peña, JM .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :280-287
[6]   Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].
Augeri, DJ ;
Robl, JA ;
Betebenner, DA ;
Magnin, DR ;
Khanna, A ;
Robertson, JG ;
Wang, AY ;
Simpkins, LM ;
Taunk, P ;
Huang, Q ;
Han, SP ;
Abboa-Offei, B ;
Cap, M ;
Xin, L ;
Tao, L ;
Tozzo, E ;
Welzel, GE ;
Egan, DM ;
Marcinkeviciene, J ;
Chang, SY ;
Biller, SA ;
Kirby, MS ;
Parker, RA ;
Hamann, LG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037
[7]   Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro [J].
Bacha, U ;
Barrila, J ;
Velazquez-Campoy, A ;
Leavitt, SA ;
Freire, E .
BIOCHEMISTRY, 2004, 43 (17) :4906-4912
[8]   Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight [J].
Baskin, DG ;
Lattemann, DF ;
Seeley, RJ ;
Woods, SC ;
Porte, D ;
Schwartz, MW .
BRAIN RESEARCH, 1999, 848 (1-2) :114-123
[9]   Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation [J].
Baum, EZ ;
Ding, WD ;
Siegel, MM ;
Hulmes, J ;
Bebernitz, GA ;
Sridharan, L ;
Tabei, K ;
Krishnamurthy, G ;
Carofiglio, T ;
Groves, JT ;
Bloom, JD ;
DiGrandi, M ;
Bradley, M ;
Ellestad, G ;
Seddon, AP ;
Gluzman, Y .
BIOCHEMISTRY, 1996, 35 (18) :5847-5855
[10]  
Bayés M, 2006, METHOD FIND EXP CLIN, V28, P31